Cyclo Therapeutics : CYTH Investor Presentation February 2022.pdf

NASDAQ: CYTH cyclotherapeutics.com

Corporate Presentation

Forward-Looking Statements

2

Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other publications of Cyclo Therapeutics, Inc. Forward-looking statements are identified by words such as "anticipates", "projects", "expects", "plans", "intends", "believes", "estimates", "target", and other similar expressions that indicate trends and future events.

The market data and certain other statistical information used throughout this presentation are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on the Company's good faith estimates. In addition, this presentation includes summaries of scientific activities and outcomes that have been condensed to aid the reader in gaining general understanding.

The information about Cyclo Therapeutics, Inc. and its subsidiaries is solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state.

Factors that could cause the Company's results to differ materially from those expressed in forward looking statements include, without limitation, the Company's need for additional capital; the Company's reliance on its Trappsol® Cyclo™ product, which may never receive regulatory approval; the Company's ability to commercialize any of its proposed drug products if it receives regulatory approval; the outcome of the Company's clinical trials, which may not support the Company's product claims or may result in adverse side effects; the cost and timing of the Company's clinical trials; the Company's reliance on third parties to conduct clinical trials and to produce its products; and other risks associated with being a clinical stage biotechnology company.

This presentation is not to be copied, transmitted, displayed, distributed (for compensation or otherwise), or altered in any way without the prior written consent of Cyclo Therapeutics, Inc.

NASDAQ: CYTH cyclotherapeutics.com

Platform Technology Pipeline:

3

Trappsol® Cyclo™ allows for a multiple shots on goal model

Program

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Milestones

Trappsol® Cyclo™	Niemann-Pick	(Pivotal Phase 3 Study)
Site activation ongoing
Disease Type C
	and currently enrolling
		patients

Trappsol® Cyclo™	Alzheimer's
Disease

Open IND for Phase 2 study

Orphan Drug Designation in U.S. | Fast Track Status in U.S.| Potential for Priority Review Voucher (PRV) in U.S Orphan Designation in EU | EMA Pediatric Investigational Plan Adopted

NASDAQ: CYTH cyclotherapeutics.com

Leadership Team with Proven Experience

4

N. Scott Fine	Joshua M. Fine
Chief Executive Officer & Director	Chief Financial Officer

Lise Lund Kjems, MD, PhD	Michael Lisjak
Chief Medical Officer	Chief Regulatory Officer

Sharon H. Hrynkow, Ph.D.	Lori McKenna Gorski
Chief Scientific Officer	Global Head of Patient Advocacy

Jeffrey L. Tate, Ph.D.

Chief Operating Officer, Chief Quality Officer & Director

NASDAQ: CYTH cyclotherapeutics.com

5

Niemann-Pick

Disease Type C

Ongoing Pivotal

Phase 3 Study

NASDAQ: CYTH cyclotherapeutics.com